StocksFundsScreenerSectorsWatchlists
HZNP

HZNP - Horizon Therapeutics Plc Stock Price, Fair Value and News

116.30USD0.00 (0.00%)Market Closed

Market Summary

HZNP
USD116.300.00
Market Closed
0.00%

HZNP Stock Price

View Fullscreen

HZNP RSI Chart

HZNP Valuation

Market Cap

26.6B

Price/Earnings (Trailing)

60.8

Price/Sales (Trailing)

7.31

EV/EBITDA

25.73

Price/Free Cashflow

27.79

HZNP Price/Sales (Trailing)

HZNP Profitability

EBT Margin

12.18%

Return on Equity

8.25%

Return on Assets

4.71%

Free Cashflow Yield

3.6%

HZNP Fundamentals

HZNP Revenue

Revenue (TTM)

3.6B

Rev. Growth (Yr)

7.82%

Rev. Growth (Qtr)

13.57%

HZNP Earnings

Earnings (TTM)

438.0M

Earnings Growth (Yr)

108.4%

Earnings Growth (Qtr)

132.37%

Breaking Down HZNP Revenue

Last 7 days

0.3%

Last 30 days

11.3%

Last 90 days

12.7%

Trailing 12 Months

84.5%

How does HZNP drawdown profile look like?

HZNP Financial Health

Current Ratio

4.27

Debt/Equity

0.16

Debt/Cashflow

1.22

HZNP Investor Care

Buy Backs (1Y)

0.60%

Diluted EPS (TTM)

1.87

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20233.6B3.6B00
20223.8B3.8B3.7B3.6B
20212.2B2.6B3.0B3.2B
20201.4B1.5B1.8B2.2B
20191.3B1.3B1.3B1.3B
20181.1B1.1B1.1B1.2B
2017997.3M1.0B1.1B1.1B
2016848.6M933.1M915.3M981.1M
2015358.2M464.9M616.3M757.0M
2014117.2M172.2M223.2M297.0M
201324.6M31.2M48.0M74.0M
20128.1M11.3M18.4M18.8M
20113.5M4.7M5.8M6.9M
20100002.4M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Horizon Therapeutics Plc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Oct 06, 2023
desjardin michael a.
back to issuer
-14,776,600
116
-126,838
evp, technical operations
Oct 06, 2023
watkins thomas
back to issuer
-12,867,100
116
-110,447
-
Oct 06, 2023
himawan jeff
back to issuer
-4,264,950
116
-36,609
-
Oct 06, 2023
walbert timothy p
back to issuer
-24,236,500
116
-208,039
chairman, president and ceo
Oct 06, 2023
witz pascale
back to issuer
-2,990,790
116
-25,672
-
Oct 06, 2023
mahony susan
back to issuer
-1,088,690
116
-9,345
-
Oct 06, 2023
grey michael g
back to issuer
-5,595,610
116
-48,031
-
Oct 06, 2023
mcilvenny patrick
back to issuer
-800,821
116
-6,874
chief accounting officer
Oct 06, 2023
watkins thomas
back to issuer
-6,518,520
116
-55,953
-
Oct 06, 2023
daniel william f
back to issuer
-3,718,100
116
-31,915
-

1–10 of 50

Which funds bought or sold HZNP recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 12, 2024
Financial Synergies Wealth Advisors, Inc.
sold off
-100
-1,480
-
-%
Mar 29, 2024
Kapitalo Investimentos Ltda
sold off
-100
-45,048,500
-
-%
Mar 28, 2024
Newbridge Financial Services Group, Inc.
sold off
-100
-4,628
-
-%
Mar 27, 2024
NOMURA HOLDINGS INC
sold off
-100
-28,922,500
-
-%
Mar 22, 2024
PNC Financial Services Group, Inc.
sold off
-100
-512,390
-
-%
Mar 21, 2024
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND
sold off
-100
-30,575,400
-
-%
Mar 11, 2024
Wahed Invest LLC
sold off
-100
-405,262
-
-%
Mar 11, 2024
VANGUARD GROUP INC
sold off
-100
-2,497,450,000
-
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
sold off
-100
-80,793,300
-
-%
Mar 01, 2024
ROYAL LONDON ASSET MANAGEMENT LTD
sold off
-100
-9,605,420
-
-%

1–10 of 44

Are Funds Buying or Selling HZNP?

Are funds buying HZNP calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own HZNP
No. of Funds

Unveiling Horizon Therapeutics Plc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
9.37%
21,236,103
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 07, 2023
blackrock inc.
6.5%
14,794,254
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 03, 2022
blackrock inc.
5.7%
13,008,024
SC 13G/A
Feb 11, 2021
renaissance technologies llc
3.08%
6,798,963
SC 13G/A
Feb 10, 2021
vanguard group inc
9.03%
19,920,258
SC 13G/A
Feb 08, 2021
fmr llc
-
0
SC 13G
Jan 29, 2021
blackrock inc.
6.4%
14,206,978
SC 13G/A
Feb 12, 2020
vanguard group inc
9.12%
17,089,414
SC 13G/A

Horizon Therapeutics Plc News

Latest updates
Yahoo Finance5 months ago
The Motley Fool11 months ago

Horizon Therapeutics Plc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue13.6%9458329429258768851,0141,037833342745636463356364335321280356325303
Gross Profit16.3%725623701691646670773785632242583485341258269246231192257234211
Operating Expenses-0.9%582588527531558476540454493402343256303275214197206194174172201
  S&GA Expenses-4.2%434453373398398373399360355332277226222248185172167172175162177
  R&D Expenses11.8%15013411811410310380.0090.0014058.00-9.4830.0081.0027.0029.0025.0028.0022.0020.0021.0024.00
EBITDA Margin7.7%0.27*0.25*0.28*0.29*0.32*0.34*0.28*0.30*0.29*0.27*0.33*0.29*---------
Interest Expenses-28.7%31.0044.0027.0038.0014.0028.0012.0030.0013.0019.003.0019.003.0027.006.0022.0034.0016.0045.0012.0040.00
Income Taxes123.1%8.00-35.4834.00-0.764.00-31.5238.00-19.30-42.48-47.7539.00-91.0883.00-19.03-555-30.56-4.87-1.92-49.05-1.275.00
Earnings Before Taxes604.4%13519.0015413565.00173211307116-1712302023.00-32.6237.00-12.33-9.99-34.7853.0032.00-20.13
EBT Margin16.6%0.12*0.10*0.15*0.16*0.20*0.21*0.14*0.16*0.15*0.12*0.18*0.11*---------
Net Income132.4%12755.0012013661.00204173327158-123191293-80.01-13.5959318.00-5.12-32.8610233.00-24.75
Net Income Margin15.6%0.12*0.10*0.14*0.16*0.20*0.23*0.17*0.19*0.20*0.13*0.18*0.44*---------
Free Cashflow129.9%14362.0040235223920252238475.00-22.0637395.00---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets3.4%9,2998,9939,1159,0288,8538,7408,6788,6098,2077,8476,0735,7674,5384,3154,4363,7213,7083,9363,9424,0193,990
  Current Assets8.9%3,9223,6033,6533,4123,2032,9482,8002,4142,1751,8313,0702,7321,4891,4141,6861,4791,4021,5601,5461,3391,235
    Cash Equivalents6.6%2,4652,3122,3532,1311,8931,6431,5801,0698128122,0801,7257187551,0768848661,033959807710
  Inventory3.5%17016417019020422715223725923875.0077.0066.0068.0054.0059.0051.0052.0051.0053.0050.00
  Net PPE1.8%36235634131830229529228622020218915613914230.0026.0025.0022.0020.0017.0018.00
  Goodwill0%1,0111,0111,0111,0111,0111,0671,0671,0691,069663414414414414414414414414414426426
  Current Liabilities3.7%918885949861791825887854853774876784985592723636637895709692726
    LT Debt, Current------------------250---
Shareholder's Equity4.2%5,3115,0965,0725,0344,9464,8184,6724,4504,0743,8554,0253,7972,3622,1882,1851,5561,5211,5041,1901,051987
  Retained Earnings19.7%772645590606584523319145-181-339-215-406-699-619-605-1,198-1,216-1,211-1,178-1,414-1,440
  Additional Paid-In Capital1.6%4,5224,4494,4744,4254,3814,3154,3734,3114,2604,2004,2464,2093,0682,8142,7982,7612,7442,7222,3752,3382,307
Shares Outstanding0.2%229229227229230229227226225224204212---------
Float-----18,300---20,900---11,000---4,500---2,700
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations87.0%16186.0042636624921653941189.00-3.73410109100-62.5919188.0091.0056.0010985.0062.00
  Share Based Compensation3.7%60.0058.0045.0045.0045.0047.0049.0055.0054.0061.0033.0030.0027.0056.0024.0018.0021.0028.0028.0028.0031.00
Cashflow From Investing52.0%-20.03-41.75-49.07-32.02-12.18-40.72-36.84-142-85.66-2,729-65.43-22.37-158-218-12.53-4.471.00-1.8531.009.00-0.10
Cashflow From Financing110.3%9.00-88.13-160-94.3717.00-11010.00-8.26-0.531,4694.0092020.00-39.6112.00-63.81-25921.0010.002.00-23.82
  Buy Backs---162113-----------------

HZNP Income Statement

2023-06-30
Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) - USD ($)
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
Net sales$ 944,959,000$ 876,411,000$ 1,777,018,000$ 1,761,656,000
Cost of goods sold219,958,000230,216,000428,521,000445,278,000
Gross profit725,001,000646,195,0001,348,497,0001,316,378,000
OPERATING EXPENSES:    
Research and development150,035,000103,246,000284,183,000206,378,000
Selling, general and administrative434,125,000398,221,000887,479,000770,955,000
Impairment of goodwill056,171,000056,171,000
Gain on sale of asset(2,000,000) (2,000,000) 
Total operating expenses582,160,000557,638,0001,169,662,0001,033,504,000
Operating income142,841,00088,557,000178,835,000282,874,000
OTHER EXPENSE, NET:    
Interest expense, net(12,098,000)(21,409,000)(27,638,000)(42,665,000)
Foreign exchange gain326,00028,000417,000448,000
Other income (expense), net4,183,000(2,389,000)2,840,000(3,131,000)
Total other expense, net(7,589,000)(23,770,000)(24,381,000)(45,348,000)
Income before expense (benefit) for income taxes135,252,00064,787,000154,454,000237,526,000
Expense (benefit) for income taxes8,181,0003,813,000(27,301,000)(27,709,000)
Net income$ 127,071,000$ 60,974,000$ 181,755,000$ 265,235,000
Net income per ordinary share—basic$ 0.56$ 0.27$ 0.80$ 1.16
Weighted average ordinary shares outstanding—basic228,743,143230,020,004228,571,356229,559,715
Net income per ordinary share—diluted$ 0.54$ 0.26$ 0.78$ 1.12
Weighted average ordinary shares outstanding—diluted233,935,591236,166,384233,938,149236,077,147
OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX    
Foreign currency translation adjustments$ 1,409,000$ (1,433,000)$ 794,000$ (1,893,000)
Pension and other post-employment benefit plan remeasurements179,000(547,000)2,003,000(222,000)
Interest rate swap contracts designated as cash flow hedges13,339,0002,011,0006,287,0002,011,000
Other comprehensive income (loss)14,927,00031,0009,084,000(104,000)
Comprehensive income$ 141,998,000$ 61,005,000$ 190,839,000$ 265,131,000

HZNP Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
CURRENT ASSETS:  
Cash and cash equivalents$ 2,464,623$ 2,352,833
Restricted cash4,7914,755
Accounts receivable, net717,417676,347
Inventories, net170,325169,559
Prepaid expenses and other current assets564,808449,349
Total current assets3,921,9643,652,843
Property, plant and equipment, net362,326340,509
Developed technology and other intangible assets, net2,486,5652,664,777
In-process research and development810,000810,000
Goodwill1,010,5381,010,538
Deferred tax assets, net444,306431,814
Other long-term assets263,042204,135
Total assets9,298,7419,114,616
CURRENT LIABILITIES:  
Accounts payable85,543155,800
Accrued expenses and other current liabilities496,669457,557
Accrued trade discounts and rebates319,469319,780
Long-term debt-current portion16,00016,000
Total current liabilities917,681949,137
LONG-TERM LIABILITIES:  
Long-term debt, net2,541,4582,546,837
Deferred tax liabilities, net264,815342,017
Other long-term liabilities263,828204,451
Total long-term liabilities3,070,1013,093,305
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY:  
Ordinary shares, $0.0001 nominal value; 600,000,000 shares authorized at June 30, 2023 and December 31, 2022; 229,323,393 and 227,625,913 shares issued at June 30, 2023 and December 31, 2022, respectively; and 228,939,027 and 227,241,547 shares outstanding at June 30, 2023 and December 31, 2022, respectively2323
Treasury stock, 384,366 ordinary shares at June 30, 2023 and December 31, 2022(4,585)(4,585)
Additional paid-in capital4,522,1454,474,199
Accumulated other comprehensive income21,61212,528
Retained earnings771,764590,009
Total shareholders’ equity5,310,9595,072,174
Total liabilities and shareholders' equity$ 9,298,741$ 9,114,616
HZNP
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
 CEO
 WEBSITEhorizontherapeutics.com
 INDUSTRYPharmaceuticals
 EMPLOYEES2190

Horizon Therapeutics Plc Frequently Asked Questions


What is the ticker symbol for Horizon Therapeutics Plc? What does HZNP stand for in stocks?

HZNP is the stock ticker symbol of Horizon Therapeutics Plc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Horizon Therapeutics Plc (HZNP)?

As of Wed Apr 03 2024, market cap of Horizon Therapeutics Plc is 26.63 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HZNP stock?

You can check HZNP's fair value in chart for subscribers.

What is the fair value of HZNP stock?

You can check HZNP's fair value in chart for subscribers. The fair value of Horizon Therapeutics Plc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Horizon Therapeutics Plc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HZNP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Horizon Therapeutics Plc a good stock to buy?

The fair value guage provides a quick view whether HZNP is over valued or under valued. Whether Horizon Therapeutics Plc is cheap or expensive depends on the assumptions which impact Horizon Therapeutics Plc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HZNP.

What is Horizon Therapeutics Plc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 03 2024, HZNP's PE ratio (Price to Earnings) is 60.8 and Price to Sales (PS) ratio is 7.31. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HZNP PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Horizon Therapeutics Plc's stock?

In the past 10 years, Horizon Therapeutics Plc has provided 0.422 (multiply by 100 for percentage) rate of return.